Tariq Enezate1,2, Deya Alkhatib1, Joel Raja1, Viswanatha Chinta1, Mitul Patel3, Jad Omran4. 1. Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Division of Cardiovascular Diseases, Memphis Veterans Affairs Medical Center, Memphis, TN, USA. 3. Sulpizio Cardiovascular Center, University of California San Diego, San Diego, CA, USA. 4. Sharp HealthCare System, 5555 Grossmont Center Dr. La Mesa, San Diego, CA, 91942, USA. jad.omran@gmail.com.
Abstract
PURPOSE OF REVIEW: Management of intracardiac masses, such as right heart thrombi and catheter-related vegetations, can be challenging. Many patients are high-risk candidates for surgical extraction due to multiple comorbidities and risk of distal embolization. In this review, we highlight the advancements in percutaneous approaches for treatment of intracardiac masses utilizing AngioVac (AngioDynamic, Latham, NY). RECENT FINDINGS: With the Food and Drug Administration (FDA) approval of the AngioVac System in 2009, a growing body of evidence has proven it to be a feasible and effective tool to extract thrombi and masses from the iliocaval system and the right heart. In this review, we highlight the feasibility of AngioVac System (AngioDynamic, Latham, NY) based on the published cases series and registries. Future randomized controlled trials are needed to establish an algorithmic approach in treating intracardiac masses.
PURPOSE OF REVIEW: Management of intracardiac masses, such as right heart thrombi and catheter-related vegetations, can be challenging. Many patients are high-risk candidates for surgical extraction due to multiple comorbidities and risk of distal embolization. In this review, we highlight the advancements in percutaneous approaches for treatment of intracardiac masses utilizing AngioVac (AngioDynamic, Latham, NY). RECENT FINDINGS: With the Food and Drug Administration (FDA) approval of the AngioVac System in 2009, a growing body of evidence has proven it to be a feasible and effective tool to extract thrombi and masses from the iliocaval system and the right heart. In this review, we highlight the feasibility of AngioVac System (AngioDynamic, Latham, NY) based on the published cases series and registries. Future randomized controlled trials are needed to establish an algorithmic approach in treating intracardiac masses.
Authors: Bennet George; Anthony Voelkel; John Kotter; Andrew Leventhal; John Gurley Journal: Catheter Cardiovasc Interv Date: 2017-05-04 Impact factor: 2.692
Authors: Ahmed Al Badri; Chad Kliger; Dillon Weiss; Luigi Pirelli; Sean Wilson; Edward R DeLaney; Vladimir Jelnin; Itzhak Kronzon; Gila Perk; Jonathan M Hemli; Nirav C Patel; Suhail Raoof; Carlos E Ruiz Journal: J Invasive Cardiol Date: 2016-05 Impact factor: 2.022
Authors: Cameron W Donaldson; Joshua N Baker; Rajeev L Narayan; Tim S Provias; Andrew N Rassi; Jay S Giri; Rahul Sakhuja; Ido Weinberg; Michael R Jaff; Kenneth Rosenfield Journal: Catheter Cardiovasc Interv Date: 2015-05-13 Impact factor: 2.692